Clovis Oncology Inc. (NASDAQ:CLVS) shares shot up 1.7% on Friday . The company traded as high as $16.70 and last traded at $16.49, with a volume of 442,470 shares trading hands. The stock had previously closed at $16.21.

A number of brokerages recently weighed in on CLVS. Piper Jaffray Cos. reaffirmed a “hold” rating on shares of Clovis Oncology in a research note on Sunday, May 8th. Vetr lowered shares of Clovis Oncology from a “buy” rating to a “hold” rating and set a $17.66 price target on the stock. in a research note on Tuesday, June 7th. JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $13.00 price target on shares of Clovis Oncology in a research note on Tuesday. Zacks Investment Research raised shares of Clovis Oncology from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research note on Thursday. Finally, Credit Suisse Group AG began coverage on shares of Clovis Oncology in a research note on Monday, April 18th. They issued an “outperform” rating on the stock. Six research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Clovis Oncology has a consensus rating of “Buy” and a consensus price target of $28.98.

The stock’s market capitalization is $647.12 million. The stock has a 50 day moving average price of $14.55 and a 200 day moving average price of $16.35.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.13) by $0.06. During the same quarter last year, the business earned ($2.10) EPS. Analysts forecast that Clovis Oncology Inc. will post ($8.16) earnings per share for the current fiscal year.

Several hedge funds and institutional investors have recently modified their holdings of CLVS. Rhumbline Advisers raised its position in shares of Clovis Oncology by 6.6% in the fourth quarter. Rhumbline Advisers now owns 30,237 shares of the biopharmaceutical company’s stock worth $1,058,000 after buying an additional 1,880 shares during the period. California State Teachers Retirement System raised its position in shares of Clovis Oncology by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 51,609 shares of the biopharmaceutical company’s stock worth $1,806,000 after buying an additional 889 shares during the period. Finally, Trexquant Investment LP purchased a new position in shares of Clovis Oncology during the fourth quarter worth about $3,170,000.

Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.